vs
Side-by-side financial comparison of NEXPOINT DIVERSIFIED REAL ESTATE TRUST (NXDT) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
NEXPOINT DIVERSIFIED REAL ESTATE TRUST is the larger business by last-quarter revenue ($18.4M vs $18.3M, roughly 1.0× ROCKWELL MEDICAL, INC.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -193.1%, a 190.1% gap on every dollar of revenue. On growth, ROCKWELL MEDICAL, INC. posted the faster year-over-year revenue change (-25.6% vs -29.0%). Over the past eight quarters, NEXPOINT DIVERSIFIED REAL ESTATE TRUST's revenue compounded faster (19.9% CAGR vs -10.1%).
NexPoint Diversified Real Estate Trust is a publicly traded US real estate investment trust. It acquires, manages and optimizes a diversified portfolio covering multifamily housing, industrial facilities, offices and neighborhood retail, generating returns via rental income and long-term property value appreciation.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
NXDT vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.4M | $18.3M |
| Net Profit | $-35.5M | $-554.0K |
| Gross Margin | — | 21.1% |
| Operating Margin | -18.8% | -2.2% |
| Net Margin | -193.1% | -3.0% |
| Revenue YoY | -29.0% | -25.6% |
| Net Profit YoY | -291.1% | 26.7% |
| EPS (diluted) | $-0.73 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.4M | $18.3M | ||
| Q3 25 | $17.5M | $15.9M | ||
| Q2 25 | $21.0M | $16.1M | ||
| Q1 25 | $29.1M | $18.9M | ||
| Q4 24 | $25.9M | $24.7M | ||
| Q3 24 | $22.2M | $28.3M | ||
| Q2 24 | $22.3M | $25.8M | ||
| Q1 24 | $12.8M | $22.7M |
| Q4 25 | $-35.5M | $-554.0K | ||
| Q3 25 | $-13.7M | $-1.8M | ||
| Q2 25 | $-45.3M | $-1.5M | ||
| Q1 25 | $-34.3M | $-1.5M | ||
| Q4 24 | $-9.1M | $-756.0K | ||
| Q3 24 | $-10.0M | $1.7M | ||
| Q2 24 | $-9.8M | $343.0K | ||
| Q1 24 | $-22.7M | $-1.7M |
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | -18.8% | -2.2% | ||
| Q3 25 | -19.1% | -9.9% | ||
| Q2 25 | -0.6% | -8.4% | ||
| Q1 25 | 19.0% | -7.2% | ||
| Q4 24 | 3.6% | -2.1% | ||
| Q3 24 | -26.8% | 6.8% | ||
| Q2 24 | 2.7% | 2.0% | ||
| Q1 24 | 2.1% | -5.8% |
| Q4 25 | -193.1% | -3.0% | ||
| Q3 25 | -78.4% | -11.0% | ||
| Q2 25 | -215.1% | -9.3% | ||
| Q1 25 | -118.0% | -8.0% | ||
| Q4 24 | -35.0% | -3.1% | ||
| Q3 24 | -45.2% | 5.9% | ||
| Q2 24 | -43.9% | 1.3% | ||
| Q1 24 | -177.3% | -7.6% |
| Q4 25 | $-0.73 | $-0.01 | ||
| Q3 25 | $-0.29 | $-0.05 | ||
| Q2 25 | $-0.99 | $-0.05 | ||
| Q1 25 | $-0.80 | $-0.04 | ||
| Q4 24 | $-0.20 | $-0.02 | ||
| Q3 24 | $-0.25 | $0.04 | ||
| Q2 24 | $-0.24 | $0.01 | ||
| Q1 24 | $-0.59 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.2M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $700.1M | $37.0M |
| Total Assets | $1.1B | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $10.7M | ||
| Q3 25 | $5.3M | $13.6M | ||
| Q2 25 | $4.7M | $12.5M | ||
| Q1 25 | $9.5M | $11.4M | ||
| Q4 24 | $8.8M | $15.7M | ||
| Q3 24 | $8.5M | $12.3M | ||
| Q2 24 | $28.4M | $11.9M | ||
| Q1 24 | $20.2M | $6.6M |
| Q4 25 | $700.1M | $37.0M | ||
| Q3 25 | $739.0M | $37.0M | ||
| Q2 25 | $752.7M | $30.4M | ||
| Q1 25 | $802.7M | $31.5M | ||
| Q4 24 | $836.5M | $32.6M | ||
| Q3 24 | $842.9M | $29.1M | ||
| Q2 24 | $859.1M | $23.5M | ||
| Q1 24 | $863.0M | $20.6M |
| Q4 25 | $1.1B | $57.1M | ||
| Q3 25 | $1.1B | $57.5M | ||
| Q2 25 | $1.1B | $52.6M | ||
| Q1 25 | $1.2B | $54.0M | ||
| Q4 24 | $1.2B | $59.2M | ||
| Q3 24 | $1.2B | $57.1M | ||
| Q2 24 | $1.2B | $53.0M | ||
| Q1 24 | $1.1B | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $2.3M | ||
| Q3 25 | $835.0K | $-1.3M | ||
| Q2 25 | $75.0K | $1.8M | ||
| Q1 25 | $7.1M | $-3.5M | ||
| Q4 24 | $-11.7M | $865.0K | ||
| Q3 24 | $497.0K | $4.3M | ||
| Q2 24 | $-5.5M | $1.4M | ||
| Q1 24 | $-2.6M | $-2.4M |
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXDT
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
